Suzanne Kosmider
Overview
Explore the profile of Suzanne Kosmider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loft M, Wong V, Kosmider S, Wong R, Shapiro J, Hong W, et al.
Intern Med J
. 2024 Nov;
55(1):41-46.
PMID: 39555636
Background: Immunotherapy has emerged as a standard treatment for deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC). Pembrolizumab became widely available as a first-line (1L) option in Australia following the...
2.
Kim G, Jalali A, Gard G, Yeung J, Chau H, Gately L, et al.
Clin Colorectal Cancer
. 2024 Nov;
24(1):72-81.
PMID: 39523153
Background: Surgery improves long-term survival for resectable, liver-only metastatic colorectal cancer (mCRC). With no consensus definition of "resectable" disease, decisions regarding resectability are reliant on the expertise and judgement of...
3.
Chung H, Hyatt A, Webber K, Kosmider S, Krishnasamy M
Health Expect
. 2024 May;
27(3):e14089.
PMID: 38769867
Introduction: Despite significant advances in the management of lung cancer, patients continue to experience a high burden of unmet need impacting quality of life and outcomes of care. Achieving value-based...
4.
Chung H, Hyatt A, Kosmider S, Webber K, Krishnasamy M
Support Care Cancer
. 2023 Sep;
31(9):554.
PMID: 37659009
Purpose: Although the financial burden and impact of a cancer diagnosis has been widely described in international literature, less understood is the availability and accessibility of services to ameliorate this...
5.
Wei M, Arafat Y, Lee M, Kosmider S, Loft M, Faragher I, et al.
ANZ J Surg
. 2023 Jan;
93(10):2285-2286.
PMID: 36716258
No abstract available.
6.
Arafat Y, Loft M, Cao K, Reid F, Kosmider S, Lee M, et al.
ANZ J Surg
. 2022 Nov;
92(11):2784-2785.
PMID: 36398349
No abstract available.
7.
Mendis S, Hong W, Ananda S, Faragher I, Jones I, Croxford M, et al.
JNCI Cancer Spectr
. 2022 Jun;
6(1).
PMID: 35699496
Background: Fecal occult blood test (FOBT)-based screening for colorectal cancer (CRC) reduces mortality, with earlier stage at diagnosis a prominent feature. Other characteristics of FOBT screen-detected cancers and any implications...
8.
Loft M, Shapiro J, Lee M, Wong R, Tie J, Kosmider S, et al.
Intern Med J
. 2022 Jun;
53(9):1610-1617.
PMID: 35668542
Background: Treatment with cetuximab provides a survival benefit for patients with RAS wild-type metastatic colorectal cancer (mCRC). Practice-defining cetuximab studies utilised weekly (q1w) administration. More convenient second weekly (q2w) administration...
9.
Tie J, Cohen J, Lahouel K, Lo S, Wang Y, Kosmider S, et al.
N Engl J Med
. 2022 Jun;
386(24):2261-2272.
PMID: 35657320
Background: The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas...
10.
Chong C, Jalali A, Wong H, Loft M, Wong R, Lee M, et al.
Asia Pac J Clin Oncol
. 2022 Jan;
18(5):e363-e368.
PMID: 35073441
Background: RAS mutation testing now routinely informs the optimal management of metastatic colorectal cancer (mCRC), specifically the finding of a RAS mutation defines patients who will not benefit from treatment...